Immunoprecise Antibodies Ltd Share Price Toronto S.E.
Equities
TQY
CA87588T2020
Pharmaceuticals
Sales 2024 * | 24.59M 18.03M 1.43B | Sales 2025 * | 29.82M 21.87M 1.73B | Capitalization | 43.1M 31.61M 2.51B |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.8M -698M | Net income 2025 * | -9M -6.6M -524M | EV / Sales 2024 * | 1.75 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.45 x |
P/E ratio 2024 * |
-3.42
x | P/E ratio 2025 * |
-4.63
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on Immunoprecise Antibodies Ltd
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 28/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 04/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
1st Jan change | Capi. | |
---|---|---|
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-12.32% | 33.03B | |
+54.37% | 24.68B | |
-17.39% | 15.12B | |
-9.14% | 12.81B | |
-10.48% | 11.79B | |
-42.45% | 11.64B | |
+6.89% | 8.9B |